Segall Bryant & Hamill LLC Purchases Shares of 21,410 Haemonetics Corporation (NYSE:HAE)

Segall Bryant & Hamill LLC purchased a new stake in Haemonetics Corporation (NYSE:HAE - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm purchased 21,410 shares of the medical instruments supplier's stock, valued at approximately $1,361,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Boston Trust Walden Corp lifted its holdings in shares of Haemonetics by 22.1% in the 1st quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier's stock valued at $71,070,000 after buying an additional 202,609 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Haemonetics by 1.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock worth $77,470,000 after purchasing an additional 10,990 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Haemonetics by 20.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 966,167 shares of the medical instruments supplier's stock valued at $60,888,000 after purchasing an additional 165,118 shares during the last quarter. Northern Trust Corp lifted its holdings in Haemonetics by 16.1% in the 4th quarter. Northern Trust Corp now owns 678,261 shares of the medical instruments supplier's stock valued at $52,959,000 after purchasing an additional 93,848 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC boosted its stake in Haemonetics by 31.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 643,227 shares of the medical instruments supplier's stock worth $50,223,000 after purchasing an additional 152,042 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HAE. Citigroup upgraded Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target for the company in a research report on Wednesday, July 9th. Needham & Company LLC cut their target price on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a research note on Friday, May 9th. Wall Street Zen downgraded Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Robert W. Baird assumed coverage on Haemonetics in a research note on Thursday, June 26th. They issued an "outperform" rating and a $87.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $97.30.

Haemonetics Stock Up 0.5%

NYSE:HAE traded up $0.40 during midday trading on Wednesday, reaching $74.61. The company had a trading volume of 425,815 shares, compared to its average volume of 681,865. The firm has a market capitalization of $3.58 billion, a price-to-earnings ratio of 22.54, a PEG ratio of 1.20 and a beta of 0.39. The stock's fifty day simple moving average is $71.93 and its 200-day simple moving average is $67.84. Haemonetics Corporation has a 12-month low of $55.30 and a 12-month high of $94.99. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The business had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. During the same quarter in the previous year, the firm earned $0.90 earnings per share. The business's revenue was down 3.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.